Gyre Therapeutics Inc GYRE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GYRE is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $15.23
- Day Range
- $14.71–15.66
- 52-Week Range
- $3.15–30.40
- Bid/Ask
- $14.82 / $14.82
- Market Cap
- $1.27 Bil
- Volume/Avg
- 38,283 / 74,082
Key Statistics
- Price/Earnings (Normalized)
- 39.49
- Price/Sales
- 8.84
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 391
- Website
- https://www.gyretx.com
Valuation
|
Metric
|
GYRE
|
|---|---|
Price/Earnings (Normalized) | 39.49 |
Price/Book Value | — |
Price/Sales | 8.84 |
Price/Cash Flow | 54.39 |
Price/Earnings
GYRE
Financial Strength
|
Metric
|
GYRE
|
|---|---|
Quick Ratio | 2.51 |
Current Ratio | 2.85 |
Interest Coverage | — |
Quick Ratio
GYRE
Profitability
|
Metric
|
GYRE
|
|---|---|
Return on Assets (Normalized) | 24.46% |
Return on Equity (Normalized) | 61.94% |
Return on Invested Capital (Normalized) | 40.03% |
Return on Assets
GYRE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vgdqsbhbx | Qprkb | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tvccbmv | Phfhyy | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Brnjpwl | Mlmqjv | $105.3 Bil | |
MRNA
| Moderna Inc | Clgxpbpw | Wxhj | $47.0 Bil | |
ARGX
| argenx SE ADR | Pwrqlhcdm | Mhmkv | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nfblnzyg | Cqkg | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ypdrpnw | Glshg | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rbwdtjb | Yrdtx | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qdyqnlny | Wtgvy | $12.7 Bil | |
INCY
| Incyte Corp | Jwstvffk | Txdkr | $12.0 Bil |